Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

236 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Allogeneic Human Mesenchymal Stem Cell Infusions for Aging Frailty.
Golpanian S, DiFede DL, Khan A, Schulman IH, Landin AM, Tompkins BA, Heldman AW, Miki R, Goldstein BJ, Mushtaq M, Levis-Dusseau S, Byrnes JJ, Lowery M, Natsumeda M, Delgado C, Saltzman R, Vidro-Casiano M, Pujol MV, Da Fonseca M, Oliva AA Jr, Green G, Premer C, Medina A, Valasaki K, Florea V, Anderson E, El-Khorazaty J, Mendizabal A, Goldschmidt-Clermont PJ, Hare JM. Golpanian S, et al. J Gerontol A Biol Sci Med Sci. 2017 Oct 12;72(11):1505-1512. doi: 10.1093/gerona/glx056. J Gerontol A Biol Sci Med Sci. 2017. PMID: 28444181 Free PMC article. Clinical Trial.
Rationale and design of the allogeneiC human mesenchymal stem cells (hMSC) in patients with aging fRAilTy via intravenoUS delivery (CRATUS) study: A phase I/II, randomized, blinded and placebo controlled trial to evaluate the safety and potential efficacy of allogeneic human mesenchymal stem cell infusion in patients with aging frailty.
Golpanian S, DiFede DL, Pujol MV, Lowery MH, Levis-Dusseau S, Goldstein BJ, Schulman IH, Longsomboon B, Wolf A, Khan A, Heldman AW, Goldschmidt-Clermont PJ, Hare JM. Golpanian S, et al. Oncotarget. 2016 Mar 15;7(11):11899-912. doi: 10.18632/oncotarget.7727. Oncotarget. 2016. PMID: 26933813 Free PMC article. Clinical Trial.
Allogeneic Mesenchymal Stem Cells Ameliorate Aging Frailty: A Phase II Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
Tompkins BA, DiFede DL, Khan A, Landin AM, Schulman IH, Pujol MV, Heldman AW, Miki R, Goldschmidt-Clermont PJ, Goldstein BJ, Mushtaq M, Levis-Dusseau S, Byrnes JJ, Lowery M, Natsumeda M, Delgado C, Saltzman R, Vidro-Casiano M, Da Fonseca M, Golpanian S, Premer C, Medina A, Valasaki K, Florea V, Anderson E, El-Khorazaty J, Mendizabal A, Green G, Oliva AA, Hare JM. Tompkins BA, et al. J Gerontol A Biol Sci Med Sci. 2017 Oct 12;72(11):1513-1522. doi: 10.1093/gerona/glx137. J Gerontol A Biol Sci Med Sci. 2017. PMID: 28977399 Free PMC article. Clinical Trial.
Inflammation, stem cells and atherosclerosis genetics.
Goldschmidt-Clermont PJ, Seo DM, Wang L, Beecham GW, Liu ZJ, Vazquez-Padron RI, Dong C, Hare JM, Kapiloff MS, Bishopric NH, Pericak-Vance M, Vance JM, Velazquez OC. Goldschmidt-Clermont PJ, et al. Curr Opin Mol Ther. 2010 Dec;12(6):712-23. Curr Opin Mol Ther. 2010. PMID: 21154163 Review.
PDGFRA defines the mesenchymal stem cell Kaposi's sarcoma progenitors by enabling KSHV oncogenesis in an angiogenic environment.
Naipauer J, Rosario S, Gupta S, Premer C, Méndez-Solís O, Schlesinger M, Ponzinibbio V, Jain V, Gay L, Renne R, Chan HL, Morey L, Salyakina D, Abba M, Williams S, Hare JM, Goldschmidt-Clermont PJ, Mesri EA. Naipauer J, et al. Among authors: goldschmidt clermont pj. PLoS Pathog. 2019 Dec 27;15(12):e1008221. doi: 10.1371/journal.ppat.1008221. eCollection 2019 Dec. PLoS Pathog. 2019. PMID: 31881074 Free PMC article.
Cell signalling and motile activity.
Heldman AW, Goldschmidt-Clermont PJ. Heldman AW, et al. Symp Soc Exp Biol. 1993;47:317-24. Symp Soc Exp Biol. 1993. PMID: 8165573 Review.
236 results